Estimating anti-amyloid therapy eligibility in Alzheimer's disease: A real-world retrospective study from an Italian memory clinic. (PubMed, J Alzheimers Dis) - Sep 29, 2026 - "BackgroundAmyloid-targeting therapies (ATTs) such as donanemab may change the management of Alzheimer's disease (AD)...Concerns regarding cost-effectiveness and practical implementation persist. Early-stage AD diagnosis and precise stratification are paramount to ensure that the promise of disease-modifying therapies can be translated into tangible clinical impact."
Journal • Real-world evidence • Retrospective data • Alzheimer's Disease • CNS Disorders • CSF P-tau
|
|
Bruno Beomonte Zobel; Carlo Augusto Mallio; Caterina Bernetti; Davide Norata; Eliodoro Faiella; Elisabetta Sapio; Fabio Pilato; Fioravante Capone; Francesca Ursini; Francesco Motolese; Gabriele Annesi; Maria Luisa Di Giesi; Mariagrazia Rossi; Michele Tondo; Rosalinda Calandrelli; Silvia Antonella Selvaggi; Vincenzo Di Lazzaro
|